Veeva, Parexel forge partnership to accelerate trials
(metamorworks/iStock via Getty Images Plus) The trial technology provider and contract research organization will collaborate on tech and process solutions designed to accelerate clinical studies.
Clinical research organization (CRO) Parexel and trial tech provider Veeva Systems have announced a collaboration aimed at generating ways to accelerate clinical research through the application of technological advancement and process innovation.
According to the companies, part of the partnership will involve Parexel standardizing on Veeva’s suite of clinical operations applications, including Vault eTMF, Vault CTMS, and Vault Study Startup to streamline operations. Vault CDMS for clinical data management will also become a standard offering available from Parexel to its customers.
Parexel and Veeva Partner to Accelerate Clinical Trials
Strategic collaboration to advance clinical trial technology and processes
DURHAM, N.C. and BARCELONA, Spain, April 15, 2021 /PRNewswire/ Parexel and Veeva Systems (NYSE: VEEV) today announced a strategic collaboration to accelerate clinical trials through technology and process innovation. The unique collaboration combines the best of each company s experience across thousands of studies worldwide - Parexel as a leading clinical research organization (CRO) and Veeva as the technology innovator powering trials - to improve study efficiency and get new therapies to patients faster.
As part of the partnership, Parexel is standardizing on Veeva s suite of clinical operations applications, including Veeva Vault eTMF, Vault CTMS, and Vault Study Startup to streamline operations. Veeva Vault CDMS for clinical data management will also become a standard offering available from Parexel to its customers.
Better Buy: Veeva Systems vs Cerner fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
RALEIGH – For the second time in seven months, Jesse Lipson is filling his coffers.
The four-time 42-year-old founder has landed another $8 million for his latest venture, a software company called Real Magic. That’s on top of $6 million raised last July, bringing total fundraising to $20 million.
Its first product, aptly called Levitate, is a “keep-in-touch” marketing platform that helps businesses grow. A little more than two years after launching, Lipson says it’s taking off.
“Given all of the uncertainty in the world, we decided that having some extra money on the balance sheet was a good idea,” Lipson told WRAL TechWire.